Big pharma’s antidote to the COVID-19 waiver: is it a viable alternative?
As governments debate whether to waive COVID-19 vaccine patents, pharma companies have posed an alternative plan to help increase the vaccine rollout, Alex Baldwin finds.
What do amendments to Chinese patent laws mean for the life sciences?
Changes to China’s patent laws sees registration, review and litigation fall in line with established international IP systems, say Venable partners Keith Haddaway and Christopher Loh.
Mexico’s updated IP laws seek to avoid the patentability of plants obtained by essentially biological processes—creating issues for plant rights owners, explains Corina Silva of Uhthoff, Gómez Vega & Uhthoff.
There are many ways that experimental use exemptions provide life sciences products with essential relief from patent infringement, as Sophie Topham of Marks & Clerk explains.
NHS v Servier: unlawful means tort claim fails, but the long-running saga continues
Beatriz San Martin and Shishu Chen of Arnold & Porter Kaye Scholer unpack the latest ruling in the dispute between the NHS and pharmaceutical company Servier.
